Class I Recalls Surge To Highest Point Ever; FDA Not Sure Why
This article was originally published in The Gray Sheet
Executive Summary
The number of high-risk Class I medical device recalls skyrocketed to its highest point ever last year, leaving FDA officials to ponder what could have caused the dramatic upswing.
You may also be interested in...
Senate Hearing Questions Strength Of FDA Post-Market Surveillance
An April 13 Senate hearing billed as a look at the medical device approval process turned into a wide-ranging critique of FDA's post-market surveillance of device safety.
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?